257 related articles for article (PubMed ID: 31625933)
1. Palliative resection of primary site in advanced gastroenteropancreatic neuroendocrine tumors improves survivals.
Kıvrak Salim D; Bayram S; Gömceli İ; Çekin AH; Karaca M; Koçer M; Yıldız M
Turk J Gastroenterol; 2019 Oct; 30(10):910-916. PubMed ID: 31625933
[TBL] [Abstract][Full Text] [Related]
2. Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors.
Tierney JF; Chivukula SV; Wang X; Pappas SG; Schadde E; Hertl M; Poirier J; Keutgen XM
Surgery; 2019 Mar; 165(3):644-651. PubMed ID: 30366604
[TBL] [Abstract][Full Text] [Related]
3. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
[TBL] [Abstract][Full Text] [Related]
4. Surgery of the primary tumour in 201 patients with high-grade gastroenteropancreatic neuroendocrine and mixed neuroendocrine-non-neuroendocrine neoplasms.
Pommergaard HC; Nielsen K; Sorbye H; Federspiel B; Tabaksblat EM; Vestermark LW; Janson ET; Hansen CP; Ladekarl M; Garresori H; Hjortland GO; Sundlöv A; Galleberg R; Knigge P; Kjaer A; Langer SW; Knigge U
J Neuroendocrinol; 2021 May; 33(5):e12967. PubMed ID: 33769624
[TBL] [Abstract][Full Text] [Related]
5. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis.
Zheng M; Li Y; Li T; Zhang L; Zhou L
Cancer Med; 2019 Sep; 8(11):5128-5136. PubMed ID: 31328428
[TBL] [Abstract][Full Text] [Related]
6. Tumour grade and primary site predict patterns of recurrence and survival in patients with resected gastroenteropancreatic neuroendocrine tumors.
Watanabe A; Yip L; Hamilton TD; Loree JM; Stuart HC
Am J Surg; 2021 Jun; 221(6):1141-1149. PubMed ID: 33795127
[TBL] [Abstract][Full Text] [Related]
7. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
8. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).
Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R
Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208
[TBL] [Abstract][Full Text] [Related]
10. Ki-67 Labeling Index Variability Between Surgically Resected Primary and Metastatic Hepatic Lesions of Gastroenteropancreatic Neuroendocrine Neoplasms.
Furukawa T; Ozaka M; Takamatsu M; Takazawa Y; Inamura K; Inoue Y; Mie T; Takeda T; Kanata R; Kasuga A; Matsuyama M; Sasaki T; Takahashi Y; Sasahira N
Int J Surg Pathol; 2021 Aug; 29(5):475-481. PubMed ID: 33543658
[No Abstract] [Full Text] [Related]
11. Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs).
Scott AT; Breheny PJ; Keck KJ; Bellizzi AM; Dillon JS; O'Dorisio TM; Howe JR
Surgery; 2019 Jan; 165(1):166-175. PubMed ID: 30343949
[TBL] [Abstract][Full Text] [Related]
12. Liver Transplant for Metastatic Neuroendocrine Tumors: A Single-Center Experience in Hungary.
Korda D; Doros A; Piros L; Gerlei Z; Haboub-Sandil A; Mándli T; Fazakas J; Deák ÁP; Máthé Z
Transplant Proc; 2019 May; 51(4):1251-1253. PubMed ID: 31101208
[TBL] [Abstract][Full Text] [Related]
13. Symptomatic presentation as a predictor of recurrence in gastroenteropancreatic neuroendocrine tumors: A single institution experience over 15 years.
Baptiste GG; Postlewait LM; Ethun CG; Le N; McInnis MR; Russell MC; Winer JH; Kooby DA; Staley CA; Maithel SK; Cardona K
J Surg Oncol; 2016 Aug; 114(2):163-9. PubMed ID: 27157897
[TBL] [Abstract][Full Text] [Related]
14. Increased Grade in Neuroendocrine Tumor Metastases Negatively Impacts Survival.
Keck KJ; Choi A; Maxwell JE; Li G; O'Dorisio TM; Breheny P; Bellizzi AM; Howe JR
Ann Surg Oncol; 2017 Aug; 24(8):2206-2212. PubMed ID: 28560597
[TBL] [Abstract][Full Text] [Related]
15. Localized high-grade gastroenteropancreatic neuroendocrine tumors: Defining prognostic and therapeutic factors for a disease of increasing clinical significance.
Mosquera C; Koutlas NJ; Fitzgerald TL
Eur J Surg Oncol; 2016 Oct; 42(10):1471-7. PubMed ID: 27528467
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
[TBL] [Abstract][Full Text] [Related]
17. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine Gastroenteropancreatic Tumors: Where Are We?
Ulla Rocha JL; Salgado A; Sardina Ferreiro R; Fernandez Catalina P; Gallardo E
Surg Laparosc Endosc Percutan Tech; 2017 Feb; 27(1):36-41. PubMed ID: 27977507
[TBL] [Abstract][Full Text] [Related]
19. Clinical analysis of gastroenteropancreatic neuroendocrine tumor with liver metastasis, compared with primary hepatic neuroendocrine tumor.
Shen YH; Chen S; Zhang WT; Ji Y; Yu L; Sun HC; Qiu SJ; Ren N; Zhou J
J Cancer Res Ther; 2014 Dec; 10 Suppl():276-80. PubMed ID: 25693935
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic Features of Gastroenteropancreatic Neuroendocrine Tumors: A Single-center Experience.
Akın Telli T; Esin E; Yalçın Ş
Balkan Med J; 2020 Aug; 37(5):281-286. PubMed ID: 32573179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]